Traded Jan 5 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Dec 11, 2025 · Filed Dec 13, 2025
A United Therapeutics director sold $24K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$24,149
Shares × reported transaction price
43 days after results of Oct 29, 2025, 76 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.7% | +0.6% | +2.1% |
| 30 days | −4.9% | +1.4% | −6.3% |
| 90 days | +6.8% | −1.7% | +8.5% |
| 180 days | +9.8% | +10.9% | −1.0% |
Past results only. Not a forecast.
Traded Jan 5 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Michael Benkowitz (PRESIDENT AND COO) sold ~$335K of United Therapeutics
Scheduled in advanceMichael Benkowitz (PRESIDENT AND COO) sold ~$798K of United Therapeutics
Scheduled in advance